US 11,919,959 B2
Inhibitors of the interaction between CLEC14A and multimerin-2 for inhibition of angiogenesis
Roy Bicknell, Birmingham (GB); Peter Noy, Nottingham (GB); and Kabir Ali Khan, Toronto (CA)
Assigned to Cancer Research Technology Limited, London (GB)
Filed by Cancer Research Technology Limited, London (GB)
Filed on Aug. 13, 2020, as Appl. No. 16/992,497.
Application 16/992,497 is a continuation of application No. 15/544,323, granted, now 10,808,031, previously published as PCT/GB2016/050134, filed on Jan. 21, 2016.
Claims priority of application No. 1501004 (GB), filed on Jan. 21, 2015.
Prior Publication US 2021/0070867 A1, Mar. 11, 2021
This patent is subject to a terminal disclaimer.
Int. Cl. C07K 16/28 (2006.01); C07K 16/30 (2006.01); A61P 35/00 (2006.01); G01N 33/50 (2006.01); A61K 39/00 (2006.01)
CPC C07K 16/2851 (2013.01) [A01K 67/0278 (2013.01); A61P 35/00 (2018.01); C07K 16/30 (2013.01); G01N 33/5008 (2013.01); A01K 2217/075 (2013.01); A01K 2227/105 (2013.01); A01K 2267/0375 (2013.01); A61K 2039/505 (2013.01); C07K 2317/34 (2013.01); C07K 2317/56 (2013.01); C07K 2317/565 (2013.01); C07K 2317/70 (2013.01); C07K 2317/76 (2013.01)] 4 Claims
 
1. A method of inhibiting angiogenesis in an individual, the method comprising administering to the individual an agent that inhibits the interaction between CLEC14A and MMRN2, wherein the agent is an antibody, or an antigen-binding fragment thereof, which selectively binds CLEC14A and comprises:
(i) a heavy chain variable region comprising (a) a heavy-chain variable region CDR1 comprising the sequence of SEQ ID NO: 40; (b) a heavy-chain variable region CDR2 comprising the sequence of SEQ ID NO: 41; and (c) a heavy chain variable region CDR3 comprising the sequence of SEQ ID NO: 47; and
a light chain variable region comprising (d) a light-chain variable region CDR1 comprising the sequence of SEQ ID NO: 43; (e) a light-chain variable region CDR2 comprising the sequence DTS; and (f) a light-chain variable region CDR3 comprising the sequence of SEQ ID NO: 48; or
(ii) a heavy chain variable region comprising (a) a heavy-chain variable region CDR1 comprising the sequence of SEQ ID NO: 1; (b) a heavy-chain variable region CDR2 comprising the sequence of SEQ ID NO: 2 or SEQ ID NO: 78; and (c) a heavy chain variable region CDR3 comprising the sequence of SEQ ID NO: 3; and
a light chain variable region comprising (d) a light-chain variable region CDR1 comprising the sequence of SEQ ID NO: 4; (e) a light-chain variable region CDR2 comprising the sequence of SEQ ID NO: 5; and (f) a light-chain variable region CDR3 comprising the sequence of SEQ ID NO: 6; or
(iii) a heavy chain variable region comprising (a) a heavy-chain variable region CDR1 comprising the sequence of SEQ ID NO: 40; (b) a heavy-chain variable region CDR2 comprising the sequence of SEQ ID NO: 41; and (c) a heavy chain variable region CDR3 comprising the sequence of SEQ ID NO: 42; and
a light chain variable region comprising (d) a light-chain variable region CDR1 comprising the sequence of SEQ ID NO: 43; (e) a light-chain variable region CDR2 comprising the sequence DTS; and (f) a light-chain variable region CDR3 comprising the sequence of SEQ ID NO: 44; or
(iv) a heavy chain variable region comprising (a) a heavy-chain variable region CDR1 comprising the sequence of SEQ ID NO: 1; (b) a heavy-chain variable region CDR2 comprising the sequence of SEQ ID NO: 78; and (c) a heavy chain variable region CDR3 comprising the sequence of SEQ ID NO: 77; and
a light chain variable region comprising (d) a light-chain variable region CDR1 comprising the sequence of SEQ ID NO: 4; (e) a light-chain variable region CDR2 comprising the sequence of SEQ ID NO: 5; and (f) a light-chain variable region CDR3 comprising the sequence of SEQ ID NO: 6; or
(v) a heavy chain variable region comprising (a) a heavy-chain variable region CDR1 comprising the sequence of SEQ ID NO: 40; (b) a heavy-chain variable region CDR2 comprising the sequence of SEQ ID NO: 41; and (c) a heavy chain variable region CDR3 comprising the sequence of SEQ ID NO: 45; and
a light chain variable region comprising (d) a light-chain variable region CDR1 comprising the sequence of SEQ ID NO: 43; (e) a light-chain variable region CDR2 comprising the sequence DTS; and (f) a light-chain variable region CDR3 comprising the sequence of SEQ ID NO: 44; or
(vi) a heavy chain variable region comprising (a) a heavy-chain variable region CDR1 comprising the sequence of SEQ ID NO: 1; (b) a heavy-chain variable region CDR2 comprising the sequence of SEQ ID NO: 78; and (c) a heavy chain variable region CDR3 comprising the sequence of SEQ ID NO: 46; and
a light chain variable region comprising (d) a light-chain variable region CDR1 comprising the sequence of SEQ ID NO: 4; (e) a light-chain variable region CDR2 comprising the sequence of SEQ ID NO: 5; and (f) a light-chain variable region CDR3 comprising the sequence of SEQ ID NO: 6.